metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
versus Standard of Care (SoC)
	gemcitabine plus platin
	BCTOP-T-A01 arm A/B, 2024 BMJ 2024; 387:e079603-. NCT02641847	RCT	es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)	docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin	epiribucine and cyclophosphamide followed by docetaxel	Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery.	166 / 170	NA	trade-off	demonstrated 49 % decrease in RFS/DFS (PE)

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin

epiribucine and cyclophosphamide followed by docetaxel

Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery.

166 / 170